Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: The START study

Expert Review of Neurotherapeutics

Volumn 10, Issue 9, 2010, Pages 1399-1408

  Leone, Massimo ^a   Vila, Carlos ^b   McGown, Caroline ^c  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b Global Medical Affairs   (Spain)

^c Content Ed Net ^*  (Spain)

Author keywords

almotriptan; early intervention; headache; migraine; trigger factors; triptans

Indexed keywords

ALMOTRIPTAN;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; HUMAN; MENSTRUATION; MIGRAINE; PRIMARY MEDICAL CARE; SLEEP; STRESS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE DISEASE; EUROPE; HUMANS; MIGRAINE DISORDERS; PRIMARY HEALTH CARE; SEROTONIN RECEPTOR AGONISTS; TRYPTAMINES;

EID: 77956455470     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.119     Document Type: Article

References (67)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl. J. Med. 346, 257-270 (2002).
2. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch. Neurol. 57, 418-420 (2000).
3. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 27, 394-402 (2007).
4. Spierings EL, Ranke AH, Honkoop PC. Precipitating and aggravating factors of migraine vs. tension-type headache. Headache 41, 554-558 (2001).
5. Henry P, Auray JP, Gaudin AF et al Prevalence and clinical characteristics of migraine in France. Neurology 59, 232-237 (2002).
6. Bener A, Uduman SA Qassimi EM et al. Genetic and environmental factors associated with migraine in schoolchildren. Headache 40, 152-157 (2000).
7. Joubert J. Migraine diagnosis and treatment. Aust. Fam. Physician. 34(8), 627-632 (2005).
8. Levy D, Straussman AM, Burstein R. A critical view on the role of migraine triggers in the genesis of migraine pain. Headache 49(6), 953-957 (2009).
9. Moskowitz DA. Defning a pathway to discovery from bench to bedside: the trigeminovascular system and sensitization. Headache 48, 688-690 (2008).
10. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience 106, 793-800 (2001).
11. Knight YE, Bartsch T, Kaube K, Goadsby PJ. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J. Neurosci. 22, RC213 (2002).
12. Fields HL. Pain modulation: expectation, opidio analgesia and virtual pain. Prog. Brain Res. 122, 245-253 (2000).
13. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci. 25, 319-325 (2002).
14. Dodick DW. Migraine triggers. Headache 49(6), 958-961 (2009).
15. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22, 633-658 (2002).
16. Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 20, 687-694 (2000).
17. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET. Serotonin and migraine. Ann. NY Acad. Sci. 600, 587-598 (1990).
18. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu. Rev. Med. 44, 145-154 (1993).
19. th Edition). Silberstein SD, Lipton RB, Soloman S (Eds). Oxford University Press, Oxford, UK, 57-72 (2001).
20. Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 21, 804-812 (2001).
21. Pascual J, Falk RM, Piessens F et al. Consistent effcacy and tolerability of almotriptan in the acuste treatment of multiple migraine attacks: results of a large randomized, double-blind placebo-controlled study. Cephalalgia 20, 588-596 (2000).
22. Goadsby PJ. The 'Act when mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia 28(2), 36-41 (2008).
23. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur. Neurol. 31, 295-299 (1991).
24. Tfelt-Hansen P, Block G, Dahlöf C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20, 765-786 (2000).
25. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferes: results of the Spectrum Study. Headache 40, 792-797 (2000).
26. Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. 22, 1035-1048 (2000).
27. Ng-Mak DS, Cady R, Chen YT, Ma L, Bell CF, Hu XH. Can migraineurs accurately identify their headaches as 'migraine' at attack onset? Headache. 47(5), 645-653 (2007).
28. Linde M, Mellberg A, Dahlöf C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia 26(6), 712-721 (2006).
29. Mathew NT, Finlayson G, Smith TR et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 47(2), 189-198 (2007).
30. Goadsby PJ, Zanchin G, Geraud G et al. Early vs. non-early intervention in acute migraine-Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 28(4), 383-391 (2008). (Pubitemid 351341454)
31. Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 46, 715-725 (2006).
32. Shapero G, Dowson A, Lacoste JP, Almqvist P. Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet. Int. J. Clin. Pract. 60, 1530-1535 (2006).
33. Lanteri-Minet M, Díaz-Insa S, Leone M, Vila C, Clissold SP. Effcacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int. J. Clin. Pract. 64, 936-943 (2010)
34. nd Edition. Cephalalgia 24(Suppl. 1), 1-160 (2004).
35. Géraud G, Lanteri-Minet M, Lucas C; French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin. Ther. 26, 1305-1318 (2004).
36. Zivadinov R, Willheim K, Sepic-Grahovac D et al. Migraine and tension-type headache in Croatia: a population-based survey of precipitating factors. Cephalalgia 23, 336-343 (2003).
37. Turner LC, Molgaard CA, Gardner CH, Rothrock JF, Stang PE. Migraine trigger factors in non-clinical Mexican-American population in San Diego county: implications for etiology. Cephalalgia 15, 523-530 (1995).
38. Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 53, 65-72 (1993).
39. Chabriat H, Danchot J, Michel P, Joire JE, Henry P. Precipitating factors of headache. A prospective study in a national control-matched survey in migraineurs and nonmigraineurs. Headache 39, 335-338 (1999).
40. Ierusalimschy R, Moreira Filho PF. Precipitating factors of migraine attacks in patients with migraine without aura. Arq. Neuropsiquiatr. 60, 609-613 (2002).
41. Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 44, 865-872 (2004).
42. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J. Health Soc. Behav. 24, 385-396 (1983).
43. Radat F, Mekies C, Géraud G. Anxiety, stress and coping behaviours in primary care migraine patients: results of the SMILE study. Cephalalgia 28(11), 1115-1125 (2008).
44. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey. Headache 43(1), 19-26 (2003).
45. Marcus D. Chronic headache: the importance of trigger identifcation. Headache Pain 14, 139-144 (2003).
46. Scher AI, Midgette, Lipton RB. Risk factors for headache chronifcation. Headache 48, 16-25 (2008).
47. Martin PR. How do trigger factors acquire the capacity to precipitate headaches? Behav. Res. Ther. 39, 545-554 (2001).
48. Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Effcacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol. Sci. 27(2), S193-S197 (2006).
49. Allais G, Castagnoli Gabellari I, De Lorenzo C, Mana O, Benedetto C. Menstrual migraine: clinical and therapeutic aspects. Expert Rev. Neurother. 7(9), 1105-1120 (2007).
50. Facchinetti F, Bonellie G, Kagasniemi P, Pascual J, Schuaib A. The effcacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study group. Obstet. Gynecol. 86(6), 911-916(1995).
51. Landy S, Savani N, Schackelford SJ, Loftus J, Jones M. Effcacy and tolerability of sumatriptan tablets administered during the mild phase of menstrually associated migraine. Int. J. Clin. Pract. 58(10), 913-919 (2004).
52. Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Effcacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 44(2), 120-130 (2004).
53. Nett R, Landy S, Shackleford S, Richardson MS, Ames M, Lener M. Pain-free effcacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet. Gynecol. 102(4), 835-842 (2003).
54. Silberstein S. The effcacy of zolmitriptan is unaffected by relationship to menses. Cephalalgia 21(4), 241-248 (2001).
55. Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C. Effcacy of oral naratriptan in the treatment of menstrually related migraine. Eur. J. Neurol. 12(10), 774-781 (2005).
56. Lambert GA, Zagami AS. The mode of action of migraine triggers: a hypothesis. Headache 49, 253-275 (2009).
57. Sobel N, Prabhakaran V, Zhao Z et al. Time course of odorant-induced activation in the human primary olfactory cortex. J. Neurophysiol. 83, 537-551 (2000).
58. Piper R. Effects of spreading depression on physiological activation of the cerebral cortex in the cat. In: Migraine And Other Headaches: The Vascular Symptoms. Olesen J (Ed.). Raven Press, NY, USA, 177-180 (1991).
59. Dietrich T, Krings T, Neulen J et al. Effects of blood estrogen level on cortical activation patterns during cognitive activation as measured by function MRI. Neuroimage 13, 425-432 (2001).
60. Chakravarty A. How triggers trigger acute migraine attacks: a hypothesis. Med. Hypotheses 74(4), 750-753 (2010).
61. Freitag FG, Finlayson G, Rapoport AM et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AZERT 12.5 mg time versus intensity migraine study (AIMS). Headache 47, 519-530 (2007).
62. Edmeads J. Understanding the needs of migraine patients. Drugs 66 (Suppl. 3), 1-8 (2006).
63. Meyer H. Pharmacological management for the adult migraine sufferer. J. Neurosci. Nurs. 41(6), 348-352 (2009).
64. Foley KA, Cady R, Martin V. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 45(5), 538-545 (2005).
65. Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia 28 (Suppl. 2), 28-35 (2008).
66. Dodick DW. Applying the benefts of the AwM study in the clinic. Cephalalgia 28(Suppl. 2), 42-49 (2008).
67. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 43(1), 36-43 (2003).